Improvement of the synthesis and pharmacokinetic properties of chromenotriazolopyrimidine MDM2-p53 protein-protein inhibitors

被引：35

作者：

Beck, Hilary P. ^{[1
]}

DeGraffenreid, Michael ^{[1
]}

Fox, Brian ^{[1
]}

Allen, John G. ^{[2
]}

Rew, Yosup ^{[1
]}

Schneider, Stephen ^{[3
]}

Saiki, Anne Y. ^{[4
]}

Yu, Dongyin ^{[4
]}

Oliner, Jonathan D. ^{[4
]}

Salyers, Kevin ^{[5
]}

Ye, Qiuping ^{[6
]}

Olson, Steven ^{[1
]}

机构：

[1] Amgen Inc, Chem Res & Discovery, San Francisco, CA 94080 USA

[2] Amgen Inc, Chem Res & Discovery, Thousand Oaks, CA 91320 USA

[3] Amgen Inc, Chem Res & Discovery, Cambridge, MA 02142 USA

[4] Amgen Inc, Oncol Res, Thousand Oaks, CA 91320 USA

[5] Amgen Inc, PKDM, Thousand Oaks, CA 91320 USA

[6] Amgen Inc, PKDM, San Francisco, CA 94080 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2011年 / 21卷 / 09期

关键词：

Oncology; Protein-protein interaction; Pharmacokinetics; SMALL-MOLECULE INHIBITORS; CANCER-THERAPY; P53; AMPLIFICATION; APOPTOSIS; STABILITY; BINDING;

D O I：

10.1016/j.bmcl.2010.11.027

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Human murine double minute 2 (MDM2) is a negative regulator of p53, which plays an important role in cell cycle and apoptosis. We report several optimizations to the synthesis of the chromenotriazolopyrimidine series of MDM2-p53 protein-protein interaction inhibitors. Additionally, the in vitro and in vivo stability, pharmacokinetic properties and solubility were improved through N-substitution. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：2752 / 2755

页数：4

共 50 条

[1] Isoindolinone based inhibitors of the MDM2-p53 protein-protein interaction
Kemp, SJ
Hardcastle, IR
Ahmed, SU
Atatreh, NA
Barrett, P
Endicott, JA
Golding, BT
Griffin, RJ
Gruber, J
Hutton, C
Lunec, J
Noble, MEM
Reid, RJ
Riedinger, C
Smyth, LA
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U2735 - U2736
[2] Design and synthesis of dual inhibitors of the MDM2-p53 and MDMX-p53 protein-protein interactions
Adhikari, Santosh
Cano, Celine
Golding, Bernard
Hardcastle, Ian
Harnor, Suzannah
Jennings, Claire
Lunec, John
Myers, Stephanie
Newell, D.
Reeks, Judith
Shouksmith, Andrew
Tudhope, Sue
Wedge, Steve
Willmore, Elaine
Wittner, Anita
Zhao, Yan
Griffin, Roger
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
[3] Selective and Potent Morpholinone Inhibitors of the MDM2-p53 Protein-Protein Interaction
Gonzalez, Ana Z.
Eksterowicz, John
Bartberger, Michael D.
Beck, Hilary P.
Canon, Jude
Chen, Ada
Chow, David
Duquette, Jason
Fox, Brian M.
Fu, Jiasheng
Huang, Xin
Houze, Jonathan B.
Jin, Lixia
Li, Yihong
Li, Zhihong
Ling, Yun
Lo, Mei-Chu
Long, Alexander M.
McGee, Lawrence R.
McIntosh, Joel
McMinn, Dustin L.
Oliner, Jonathan D.
Osgood, Tao
Rew, Yosup
Saiki, Anne Y.
Shaffer, Paul
Wortman, Sarah
Yakowec, Peter
Yan, Xuelei
Ye, Qiuping
Yu, Dongyin
Zhao, Xiaoning
Zhou, Jing
Olson, Steven H.
Medina, Julio C.
Sun, Daqing
JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (06) : 2472 - 2488
[4] Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction
Hardcastle, IR
Ahmed, SU
Atkins, H
Calvert, AH
Curtin, NJ
Farnie, G
Golding, BT
Griffin, RJ
Guyenne, S
Hutton, C
Källbad, P
Kemp, SJ
Kitching, MS
Newell, DR
Norbedo, S
Northen, JS
Reid, RJ
Saravanan, K
Willems, HMG
Lunec, J
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (05) : 1515 - 1520
[5] Triarylpyrroles, dual inhibitors of the MDM2-p53 and MDMX-p53 protein-protein interactions
Blackburn, T.
Ahmed, H.
Coxon, C. R.
Golding, B. T.
Griffin, R. J.
Newell, H.
Liu, J.
Lu, X.
Lunec, J.
Hardcastle, I. R.
EJC SUPPLEMENTS, 2010, 8 (07): : 139 - 140
[6] Discovery of MDM2-p53 and MDM4-p53 protein-protein interactions small molecule dual inhibitors
Espadinha, Margarida
Lopes, Elizabeth A.
Marques, Vanda
Amaral, Joana D.
dos Santos, Daniel J. V. A.
Mori, Mattia
Daniele, Simona
Piccarducci, Rebecca
Zappelli, Elisa
Martini, Claudia
Rodrigues, Cecilia M. P.
Santos, Maria M. M.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 241
[7] Inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold.
Hardcastle, IR
Ahmed, SU
Barrett, PA
Endicott, JA
Golding, BT
Griffin, RJ
Gruber, J
Hutton, C
Kemp, SJ
Lunec, J
Noble, ME
Riedinger, C
Smyth, LA
CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9053S - 9054S
[8] MDM2-p53 protein-protein interaction inhibitors: A-ring substituted isoindolinones
Watson, Anna F.
Liu, Junfeng
Bennaceur, Karim
Drummond, Catherine J.
Endicott, Jane A.
Golding, Bernard T.
Griffin, Roger J.
Haggerty, Karen
Lu, Xiaohong
McDonnell, James M.
Newell, David R.
Noble, Martin E. M.
Revill, Charlotte H.
Riedinger, Christiane
Xu, Qing
Zhao, Yan
Lunec, John
Hardcastle, Ian R.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (19) : 5916 - 5919
[9] Identification of substituted isoindolinones as potent inhibitors of the MDM2-p53 protein-protein interaction
Watson, Anna
Liu, Junfeng
Armstrong, Elizabeth
Blackburn, Timothy
Endicott, Jane A.
Golding, Bernard T.
Griffin, Roger J.
Lu, Xiaohong
Newell, David R.
Noble, Martin E. M.
Riedinger, Christiane
Lunec, John
Hardcastle, Ian R.
MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
[10] Development of a potent class of small molecule inhibitors of the MDM2-p53 protein-protein interaction
Fazal, Lynsey
Ahn, Maria
Bevan, Luke
Buck, Ildiko
Castro, Juan
Chessari, Gianni
Cons, Ben
Hearn, Keisha
Howard, Steven
Johnson, Chris
Reeks, Judith
Tamanini, Emiliano
Thompson, Neil
Walton, Hugh
Williams, Pamela
Bawn, Ruth H.
Blackburn, Tim J.
Cano, Celine
Cully, Sarah J.
Golding, Bernard
Griffin, Roger
Haggerty, Karen
Hardcastle, Ian
Newell, Herbie
Noble, Martin
Thomas, Huw
Willmore, Elaine
Zhao, Yan
Wedge, Steve
CANCER RESEARCH, 2018, 78 (13)

← 1 2 3 4 5 →